FIELD: biotechnology.
SUBSTANCE: there are presented: binding and multispecific binding proteins, which bind target antigen, where VHX contains one or more inactivating mutations Y33A, R50E, R59E and Y105A and/or cysteine substitution G44C and/or VLX contains cysteine substitution Q100C, methods for production and use thereof. Also disclosed are nucleic acid molecules, expression vectors, host cells and pharmaceutical compositions containing them.
EFFECT: group of inventions is used to treat disorders in which antigen activity has a negative effect on the body, in particular oncological diseases.
43 cl, 12 tbl, 18 dwg, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TUMOR-TARGETING AGONIST CD28 ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2837821C1 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| IMPROVED ANTIGEN-BINDING RECEPTORS | 2018 |
|
RU2825816C2 |
| BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| ANTIBODIES WHICH BIND TO SORTILIN AND INHIBIT THE BINDING OF PROGRANULIN | 2016 |
|
RU2735639C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| ANTIBODIES THAT BIND TO CANCER CELLS AND PROVIDE TARGETED TRANSFER OF RADIONUCLIDES TO SAID CELLS | 2020 |
|
RU2833191C2 |
| ANTIBODY-LIKE BINDING PROTEINS WITH DOUBLE VARIABLE REGIONS HAVING CROSS-CROSS ORIENTATION OF BINDING REGIONS | 2012 |
|
RU2823693C2 |
